This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Apple, Berkshire Hathaway, Pfizer, Oracle and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Berkshire Hathaway, Pfizer, Oracle and Lockheed Martin
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Analyst Reports for Apple, Berkshire Hathaway & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Berkshire Hathaway (BRK.B) and Pfizer (PFE).
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
You Can Be a Value Investor and a Bull
by Tracey Ryniec
Waiting for the hot growth stocks to crash? Forget those and look for big cap bargains as the market heats up.
You Can Be a Value Investor and a Bull
by Tracey Ryniec
Waiting for the hot growth stocks to crash? Forget those and look for big cap bargains as the market heats up.
Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
AstraZeneca (AZN) Q1 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for both earnings and sales. It maintains its financial outlook for the year.
Pfizer (PFE) Q1 Earnings Top, Biopharma Gains From Coronavirus
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings. While the coronavirus pandemic hurts sales of some Pfizer medicines, it benefited sales of others, resulting in a net positive benefit on total sales.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS
by Kinjel Shah
Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN
by Kinjel Shah
Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.71, moving +1.27% from the previous trading session.
Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany
by Zacks Equity Research
Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
Novartis To Initiate Hydroxychloroquine Study for Coronavirus
by Zacks Equity Research
Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.